Alamar Biosciences, Inc.

Alamar Biosciences, Inc. (NASDAQ: ALMR) is a commercial-stage precision proteomics company headquartered in Fremont, California, founded in 2018 by CEO Yuling Luo, with a mission to power the earliest detection of disease through ultra-high sensitivity protein biomarker analysis. The company commercializes its proprietary NULISA™ platform and ARGO™ HT fully automated, high-throughput system, which together enable single-digit attomolar detection sensitivity and highly multiplexed protein quantification from minimal biofluid samples, serving customers across drug discovery, translational research, and clinical diagnostics. Operating on a razor-and-blade business model, Alamar sells its ARGO HT instrumentation alongside recurring NULISA consumable assay kits, with key therapeutic focus areas spanning neurology, oncology, and immunology, and had accumulated over 100 installed instruments serving more than 300 customers across 25 countries by end of 2025. The company completed its NASDAQ IPO on April 17, 2026, pricing shares at $17 and generating total revenues of $74.2 million in 2025, representing approximately 195% year-over-year growth.